Daiwa Securities Group Inc. Reduces Stake in Biogen Inc. $BIIB

Daiwa Securities Group Inc. lowered its position in Biogen Inc. (NASDAQ:BIIB) by 40.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,277 shares of the biotechnology company’s stock after selling 17,798 shares during the period. Daiwa Securities Group Inc.’s holdings in Biogen were worth $4,624,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of BIIB. Empowered Funds LLC boosted its position in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 2,777 shares during the last quarter. Focus Partners Wealth boosted its position in Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in Biogen in the second quarter valued at approximately $216,000. Cerity Partners LLC boosted its position in Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after buying an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.4%

Shares of BIIB stock opened at $192.62 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market cap of $28.44 billion, a price-to-earnings ratio of 20.67 and a beta of 0.20. The stock has a 50 day simple moving average of $187.63 and a 200-day simple moving average of $183.63. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on BIIB shares. Needham & Company LLC raised Biogen from a “hold” rating to a “buy” rating and set a $255.00 price target for the company in a report on Monday. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. JPMorgan Chase & Co. boosted their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Argus raised Biogen to a “hold” rating in a report on Thursday, April 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $225.00 price target (up from $214.00) on shares of Biogen in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $217.26.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.